Plegridy

RSS

peginterferon beta-1a

Authorised
This medicine is authorised for use in the European Union.

Overview

Plegridy is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used specifically in adults with a type of MS known as relapsing-remitting MS, where the patient has flare-ups of symptoms (relapses) between periods of recovery (remissions).

Plegridy contains the active substance peginterferon beta-1a.

This EPAR was last updated on 22/03/2021

Authorisation details

Product details
Name
Plegridy
Agency product number
EMEA/H/C/002827
Active substance
peginterferon beta-1a
International non-proprietary name (INN) or common name
peginterferon beta-1a
Therapeutic area (MeSH)
Multiple Sclerosis
Anatomical therapeutic chemical (ATC) code
L03AB13
Publication details
Marketing-authorisation holder
Biogen Netherlands B.V.
Revision
22
Date of issue of marketing authorisation valid throughout the European Union
18/07/2014
Contact address

Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands

Product information

14/12/2020 Plegridy - EMEA/H/C/002827 - X/0056

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunostimulants

Therapeutic indication

Treatment of relapsing remitting multiple sclerosis in adult patients.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating